DSpace@İnönü

Combined immunosuppressive therapy in aplastic anaemia

Basit öğe kaydını göster

dc.contributor.author Osman, I.
dc.contributor.author Koc, H.
dc.contributor.author Ismet, A.
dc.contributor.author Meral, B.
dc.contributor.author Hamdi, A.
dc.contributor.author Nahide, K.
dc.contributor.author Akin, U.
dc.date.accessioned 2022-10-06T09:32:47Z
dc.date.available 2022-10-06T09:32:47Z
dc.date.issued 1995
dc.identifier.issn 09715916 (ISSN)
dc.identifier.uri http://hdl.handle.net/11616/62816
dc.description.abstract Fifteen patients with aplastic anaemia (AA) were treated with combined immunosuppressive treatment (9 of them had severe, the others had less severe AA). Cyclosporin A(CsA) was given as 12 mg/kg/daily intravenous infusions for 90 days with serum levels being monitored weekly by radioimmunoassay. Antilymphocyte globulin serum (ALG) was administered by intravenous infusion through eight hours at a dosage of 20 mg/kg/daily for eight days. Methylprednisolone (MP) was given orally as 5 mg/kg/daily, tapered every three days, for 29 days. Complete remission (CR) was observed in five severe AA patients and two less severe AA patients with therapy. Partial remission (PR) was observed in one severe AA and two less severe AA patients. No remissions were reached in four patients, two of whom had severe AA, the others had less severe AA. Relapse was observed in two patients at sixth and ninth month. Haemolysis occurred in one patient and MP was started. Only one patient died during the treatment because of infection due to febrile neutropaenia. Toxicities were reversible. Combined immunosuppressive treatment may be the treatment of choice for patients who are not eligible for bone marrow transplantation.
dc.source Indian Journal of Medical Research
dc.title Combined immunosuppressive therapy in aplastic anaemia


Bu öğenin dosyaları:

Dosyalar Boyut Biçim Göster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster